JP7256741B2 - 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 - Google Patents

感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 Download PDF

Info

Publication number
JP7256741B2
JP7256741B2 JP2019520627A JP2019520627A JP7256741B2 JP 7256741 B2 JP7256741 B2 JP 7256741B2 JP 2019520627 A JP2019520627 A JP 2019520627A JP 2019520627 A JP2019520627 A JP 2019520627A JP 7256741 B2 JP7256741 B2 JP 7256741B2
Authority
JP
Japan
Prior art keywords
recipient
antibody
composition
transplantation
transplant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520627A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530728A5 (https=
JP2019530728A (ja
Inventor
ハーマン グリフィン，
イー ワン，
レベッカ フレイ，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2019530728A publication Critical patent/JP2019530728A/ja
Publication of JP2019530728A5 publication Critical patent/JP2019530728A5/ja
Priority to JP2022020361A priority Critical patent/JP2022051954A/ja
Application granted granted Critical
Publication of JP7256741B2 publication Critical patent/JP7256741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019520627A 2016-10-12 2017-10-12 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性 Active JP7256741B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022020361A JP2022051954A (ja) 2016-10-12 2022-02-14 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662407167P 2016-10-12 2016-10-12
US62/407,167 2016-10-12
PCT/US2017/056268 WO2018071624A1 (en) 2016-10-12 2017-10-12 Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022020361A Division JP2022051954A (ja) 2016-10-12 2022-02-14 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性

Publications (3)

Publication Number Publication Date
JP2019530728A JP2019530728A (ja) 2019-10-24
JP2019530728A5 JP2019530728A5 (https=) 2020-11-12
JP7256741B2 true JP7256741B2 (ja) 2023-04-12

Family

ID=60320981

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019520627A Active JP7256741B2 (ja) 2016-10-12 2017-10-12 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
JP2022020361A Pending JP2022051954A (ja) 2016-10-12 2022-02-14 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022020361A Pending JP2022051954A (ja) 2016-10-12 2022-02-14 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性

Country Status (4)

Country Link
US (1) US20190276524A1 (https=)
EP (1) EP3526250A1 (https=)
JP (2) JP7256741B2 (https=)
WO (1) WO2018071624A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
ES2984352T3 (es) 2016-06-14 2024-10-29 Regeneron Pharma Anticuerpos anti-C5 y usos de los mismos
EP3529619B1 (en) 2016-10-19 2021-06-30 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5a in a sample
US20200123238A1 (en) * 2017-04-19 2020-04-23 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
SI3658184T1 (sl) 2017-07-27 2024-01-31 Alexion Pharmaceuticals, Inc., Formulacije z visoko koncentracijo protiteles proti-C5
CA3080187A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
CN112996561A (zh) 2018-10-30 2021-06-18 亚力兄制药公司 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528720A (ja) 2008-07-21 2011-11-24 イミューノメディクス、インコーポレイテッド 改善された治療上の特徴のための抗体の構造変異体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CN109310760A (zh) * 2016-06-07 2019-02-05 诺华股份有限公司 抗c5抗体给药方案

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011528720A (ja) 2008-07-21 2011-11-24 イミューノメディクス、インコーポレイテッド 改善された治療上の特徴のための抗体の構造変異体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ａｍｅｒｉｃａｎ Ｊｏｕｒｎａｌ ｏｆ Ｔｒａｎｓｐｌａｎｔａｔｉｏｎ （２０１１），１１， ｐ．２４０５－２４１３
Ａｍｅｒｉｃａｎ Ｊｏｕｒｎａｌ ｏｆ Ｔｒａｎｓｐｌａｎｔａｔｉｏｎ（２００９）， ９， ｐ．２３１－２３５
Ｐｅｄｉａｔｒｉｃｓ （２０１５）， １３５（２）， ｐ．ｅ５５１－ｅ５５５
Ｔｒａｎｓｐｌａｎｔａｔｉｏｎ （２０１４）， ９８， ｐ．８５７－８６３
秋葉 隆，アフェレシス療法の現状と今後の可能性 －種類と適応疾患について－，日腎会誌，日本，２００９年５１巻７号，８７５－８７７

Also Published As

Publication number Publication date
EP3526250A1 (en) 2019-08-21
WO2018071624A1 (en) 2018-04-19
JP2022051954A (ja) 2022-04-01
US20190276524A1 (en) 2019-09-12
JP2019530728A (ja) 2019-10-24

Similar Documents

Publication Publication Date Title
JP7256741B2 (ja) 感作レシピエントの腎移植における抗体関連型拒絶反応の予防における抗ｃ５抗体の有効性
US20210187054A1 (en) Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kidney transplant
US20070025987A1 (en) Method for Treating Vasculitis
US20060233797A1 (en) Treatment of inflammatory bowel disease (IBD)
US20220184208A1 (en) Anti-cd19 combination therapy
AU2018314765B2 (en) Obinutuzumab treatment of a DLBCL patient subgroup
US20200123238A1 (en) Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
US20230100100A1 (en) Treating ige-mediated allergic diseases
JP2023506732A (ja) ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
JP7705353B2 (ja) Ｃｄ３８抗体を使用する併用療法
Gazdic et al. Safety and efficacy of immunoadsorption in heart transplantation program
JP2023523096A (ja) 急性呼吸促迫症候群を治療するための組成物および方法
Dodd et al. Renal Transplant Rejection
HK40100361A (zh) 用抗il-13抗体治疗特应性皮炎的方法
JP2024511078A (ja) 抗ｉｌ－１３抗体を用いてアトピー性皮膚炎を処置する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190704

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20190704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221118

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221128

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221129

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230106

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230111

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20230224

C305 Report on accelerated appeal examination

Free format text: JAPANESE INTERMEDIATE CODE: C305

Effective date: 20230227

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230228

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230307

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230330

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230331

R150 Certificate of patent or registration of utility model

Ref document number: 7256741

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150